An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed

Merck 7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

A Randomized Trial of Early, Upfront Palliative Radiation Therapy versus Standard of Care for Patients with Highest Risk Asymptomatic or Minimally Symptomatic Bone Metastases

RANDOMIZED PHASE II/III STUDY OF VENETOCLAX (ABT 199) PLUS CHEMOIMMUNOTHERAPY FOR MYC/BCL2 DOUBLE-HIT AND DOUBLE EXPRESSING LYMPHOMAS

20-214-29 / CA045-022: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk

Merck 867:  A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable

SEntinel Lymph node Endometrial Cancer Trial: A Prospective Multicenter International Single-Arm Observational Trial(SELECT)

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MSK 18-285: A Phase 1 Trial of RO5126766 (CH5126766) in Patients with Advanced KRAS-Mutant Lung Adenocarcinomas

STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial